Completed PHASE1 INTERVENTIONAL 5-arm NCT03537404

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Sponsor: Almedis

Conditions Healthy

Interventions Narlaprevir Raltegravir Ritonavir Tenofovir Disoproxil Fumarate

Updated 8 times since 2018 Last updated: Aug 31, 2018 Started: Apr 24, 2017 Primary completion: Jun 24, 2017 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03537404, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Almedis, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE1
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Mar 2019 [monthly]

Completed PHASE1

First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Almedis
R-Pharm

Data source: R-Pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia